|
1
|
Hodis E, Watson IR, Kryukov GV, Arold ST,
Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C,
et al: A landscape of driver mutations in melanoma. Cell.
150:251–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Allen DC: Malignant melanomaHistopathology
Reporting. Springer; London: pp. 207–216. 2013, View Article : Google Scholar
|
|
3
|
Stewart BW and Wild CP: World Cancer
Report 2014. IARC Publications; Lyon: 2017
|
|
4
|
Azoury SC and Lange JR: Epidemiology, risk
factors, prevention, and early detection of melanoma. Surg Clin
North Am. 94(945–62): vii2014. View Article : Google Scholar
|
|
5
|
Topalian SL, Sznol M, McDermott DF, Kluger
HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB,
Powderly JD, et al: Survival, durable tumor remission, and
long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Atefi M, Avramis E, Lassen A, Wong DJ,
Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, et
al: Effects of MAPK and PI3K pathways on PD-L1 expression in
melanoma. Clin Cancer Res. 20:3446–3457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pal HC, Sharma S, Strickland LR, Katiyar
SK, Ballestas ME, Athar M, Elmets CA and Afaq F: Fisetin inhibits
human melanoma cell invasion through promotion of mesenchymal to
epithelial transition and by targeting MAPK and NFκB signaling
pathways. PLoS One. 9:e863382014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perkel JM: Visiting ‘noncodarnia’.
Biotechniques. 54(301): 303–304. 2013.
|
|
9
|
Ning S, Zhang J, Wang P, Zhi H, Wang J,
Liu Y, Gao Y, Guo M, Yue M, Wang L and Li X: Lnc2Cancer: A manually
curated database of experimentally supported lncRNAs associated
with various human cancers. Nucleic Acids Res. 44:D980–D985. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J
and Fang G: Up-regulated long non-coding RNA H19 contributes to
proliferation of gastric cancer cells. FEBS J. 279:3159–3165. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo M, Li Z, Wang W, Zeng Y, Liu Z and Qiu
J: Long non-coding RNA H19 increases bladder cancer metastasis by
associating with EZH2 and inhibiting E-cadherin expression. Cancer
Lett. 333:213–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khaitan D, Dinger ME, Mazar J, Crawford J,
Smith MA, Mattick JS and Perera RJ: The melanoma-upregulated long
noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer
Res. 71:3852–3862. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian Y, Zhang X, Hao Y, Fang Z and He Y:
Potential roles of abnormally expressed long noncoding RNA UCA1 and
Malat-1 in metastasis of melanoma. Melanoma Res. 24:335–341. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang L, Zhang W, Su B and Yu B: Long
noncoding RNA HOTAIR is associated with motility, invasion, and
metastatic potential of metastatic melanoma. Biomed Res Int.
2013:2510982013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen L, Yang H, Xiao Y, Tang X, Li Y, Han
Q, Fu J, Yang Y and Zhu Y: LncRNA GAS5 is a critical regulator of
metastasis phenotype of melanoma cells and inhibits tumor growth in
vivo. Onco Targets Ther. 9:4075–4087. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li H, Yu B, Li J, Su L, Yan M, Zhu Z and
Liu B: Overexpression of lncRNA H19 enhances carcinogenesis and
metastasis of gastric cancer. Oncotarget. 5:2318–2329. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liang WC, Fu WM, Wong CW, Wang Y, Wang WM,
Hu GX, Zhang L, Xiao LJ, Wan DC, Zhang JF and Waye MM: The lncRNA
H19 promotes epithelial to mesenchymal transition by functioning as
miRNA sponges in colorectal cancer. Oncotarget. 6:22513–22525.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng
R, Wang Y, Huang J, Xu M, Yan J and Yu J: lncRNA H19/miR-675 axis
represses prostate cancer metastasis by targeting TGFBI. FEBS J.
281:3766–3775. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou X, Ye F, Yin C, Zhuang Y, Yue G and
Zhang G: The interaction between MiR-141 and lncRNA-H19 in
regulating cell proliferation and migration in gastric cancer. Cell
Physiol Biochem. 36:1440–1452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi Y, Wang Y, Luan W, Wang P, Tao T,
Zhang J, Qian J, Liu N and You Y: Long non-coding RNA H19 promotes
glioma cell invasion by deriving miR-675. PLoS One. 9:e862952014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang WT, Ye H, Wei PP, Han BW, He B, Chen
ZH and Chen YQ: LncRNAs H19 and HULC, activated by oxidative
stress, promote cell migration and invasion in cholangiocarcinoma
through a ceRNA manner. J Hematol Oncol. 9:1172016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pan JX: LncRNA H19 promotes
atherosclerosis by regulating MAPK and NF-kB signaling pathway. Eur
Rev Med Pharmacol Sci. 21:322–328. 2017.PubMed/NCBI
|
|
25
|
Hyam SR, Lee IA, Gu W, Kim KA, Jeong JJ,
Jang SE, Han MJ and Kim DH: Arctigenin ameliorates inflammation in
vitro and in vivo by inhibiting the PI3K/AKT pathway and polarizing
M1 macrophages to M2-like macrophages. Eur J Pharmacol. 708:21–29.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han W, Xiong Y, Li Y, Fang W, Ma Y, Liu L,
Li F and Zhu X: Anti-arthritic effects of clematichinenoside (AR-6)
on PI3K/Akt signaling pathway and TNF-α associated with
collagen-induced arthritis. Pharm Biol. 51:13–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
